Literature DB >> 28622432

Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma.

Maria Isabel Schmidgen1, Florian Butsch1, Simin Schadmand-Fischer2, Kerstin Steinbrink1, Stephan Grabbe1, Beate Weidenthaler-Barth1, Carmen Loquai1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28622432     DOI： 10.1111/ddg.13272

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  10 in total

1.  Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.

Authors:  Kyle T Amber; Manuel Valdebran; Yuxin Lu; Sebastien De Feraudy; Kenneth G Linden
Journal:  J Dtsch Dermatol Ges       Date:  2018-02-01       Impact factor: 5.584

2.  Lokalisiertes prätibiales bullöses Pemphigoid bei einer Patientin unter Pembrolizumab-Therapie wegen eines metastasierten Melanoms.

Authors:  Kyle T Amber; Manuel Valdebran; Yuxin Lu; Sebastien De Feraudy; Kenneth G Linden
Journal:  J Dtsch Dermatol Ges       Date:  2018-02       Impact factor: 5.584

Review 3.  Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering.

Authors:  Franziska Hübner; Ewan A Langan; Andreas Recke
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 4.  Melanoma and Vitiligo: In Good Company.

Authors:  Cristina Maria Failla; Maria Luigia Carbone; Cristina Fortes; Gianluca Pagnanelli; Stefania D'Atri
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

5.  Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors:  Isabella Pospischil; Wolfram Hoetzenecker
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

6.  Pembrolizumab-induced rash in a patient with angiosarcoma.

Authors:  Justin Qian; Shelby L Kubicki; Jonathan L Curry; Richard Jahan-Tigh; Robert Benjamin; Meghan Heberton; Kelly C Nelson
Journal:  JAAD Case Rep       Date:  2022-08-27

7.  Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma.

Authors:  Anna L Cogen; Vishwas Parekh; Tara Gangadhar; Jules B Lipoff
Journal:  JAAD Case Rep       Date:  2018-01-16

Review 8.  Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.

Authors:  Ian William Tattersall; Jonathan Scott Leventhal
Journal:  Yale J Biol Med       Date:  2020-03-27

9.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.